2025 年的期刊文章 · 第 19 页

共 1491 篇,按发表时间排,新的在前,每页 40 篇。这一页是 2025-05-19 到 2025-05-07。

按期刊、按主题看 →

第 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 页

SiM Clinical Trials Optimization & Learning Theory · 发表于 2025-05-19

UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints

Mingyue Li, Zhonglong Guo, Yingjie Qiu

摘要

A primary objective of oncology dose‐finding trials for novel therapies is to determine an optimal biological dose (OBD) that is both tolerable and therapeutically beneficial for patients in subsequent clinical trials. These new therapeutic agents are more likely to induce multiple low‐ or moderate‐grade toxicities rather than dose‐limiting toxicities. Additionally, efficacy is evaluated comprehensively, differentiating between complete remission and partial remission, as well as incorporating continuous efficacy endpoints. This important issue was highlighted in the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section open forums and was a significant consideration of the FDA's “Project Optimus.” We proposed the UNITED design, a unified, transparent, and efficient Phase I/II trial design to incorporate toxicity and efficacy grades and types, as well as continuous efficacy responses, into dose‐finding and optimization. The UNITED design can handle binary, quasi‐binary, continuous, and mixed toxicity and efficacy endpoints. We further extended the UNITED design, referred to as TITE‐UNITED, to accommodate delayed toxicity and efficacy outcomes. Simulation studies showed that the UNITED and TITE‐UNITED designs have desirable operating characteristics, performing comparably to or better than existing designs. A user‐friendly software is available for practical implementation.

SiM Optimization & Learning Theory Clinical Trials Bayesian Methods · 发表于 2025-05-19

TODO: A Triple‐Outcome Double‐Criterion Optimal Design for Dose Monitoring‐and‐Optimization in Multi‐Dose Randomized Trials

Jingyi Zhang, Heng Zhou, Nolan A. Wages, Zifang Guo, Fang Liu, Thomas Jemielita, Fangrong Yan, Ruitao Lin

摘要

Detecting the efficacy signal and determining the optimal dose are critical steps to increase the probability of success and expedite the drug development in cancer treatment. After identifying a safe dose range through phase I studies, conducting a multidose randomized trial becomes an effective approach to achieve this objective. However, there have been limited formal statistical designs for such multidose trials, and dose selection in practice is often ad hoc, relying on descriptive statistics. We propose a Bayesian optimal two‐stage design to facilitate rigorous dose monitoring and optimization. Utilizing a flexible Bayesian dynamic linear model for the dose–response relationship, we employ dual criteria to assess dose admissibility and desirability. Additionally, we introduce a triple‐outcome trial decision procedure to consider dose selection beyond clinical factors. Under the proposed model and decision rules, we develop a systematic calibration algorithm to determine the sample size and Bayesian posterior probability cutoffs to optimize specific design operating characteristics. Furthermore, we demonstrate how to concurrently assess toxicity and efficacy within the proposed framework using a utility‐based risk‐benefit trade‐off. To validate the effectiveness of our design, we conduct extensive simulation studies across a variety of scenarios, demonstrating its robust operating characteristics.

SiM Survival Analysis Causal Inference · 发表于 2025-05-19

Surrogate Marker Evaluation: A Tutorial Using R

Layla Parast

摘要

The practice of using a surrogate marker to replace a primary outcome in clinical studies has become widespread. Typically, the primary outcome requires long‐term patient follow‐up, is expensive, or is invasive or burdensome for patients to measure, while the surrogate marker is not (or less so). Of course, a surrogate marker must be validated before it should be used to make a decision about the effectiveness of a treatment. There has been a tremendous amount of statistical and clinical research focused on evaluating and validating surrogate markers over the past 35 years. Although there is ongoing debate over the optimal evaluation method, the development of new approaches and insights has greatly enriched the field. In this tutorial, we describe available statistical frameworks for evaluating a surrogate marker and specifically focus on the practical implementation of the proportion of treatment effect explained framework. We consider both uncensored and censored outcomes, parametric and non‐parametric estimation, evaluating multiple surrogates, heterogeneity in the utility of the surrogate marker, surrogate evaluation from a prediction perspective, and the surrogate paradox. We include R code to implement these procedures with a follow‐along R markdown. We close with a discussion on open problems in this research area, particularly in terms of using the surrogate marker to test for treatment in a future study, which is the ultimate goal of surrogate marker evaluation.

SiM Clinical Trials · 发表于 2025-05-19

Sample Size and Power Calculations With Win Measures Based on Hierarchical Endpoints

Huiman Barnhart, Yuliya Lokhnygina, Roland Matsouaka, Susan Halabi, David Yanez, Robert J. Mentz, Frank Rockhold

摘要

Win measures, such as win ratio, win odds, net benefit, and desirability of outcome ranking (DOOR), have become popular approaches for the analysis of hierarchical endpoints in clinical studies. Sample size and power calculations with win measures based on hierarchical endpoints are often based on simulation studies that can be cumbersome. Existing sample size and power formulas require investigators to specify clinically significant and meaningful magnitudes of win measures and probability of ties that are difficult to elicit based on prior published literature or preliminary data. In this paper, we provide sample size and power calculation formulas for the four win measures. To facilitate the formula‐based sample size or power calculations, we provide formulas to compute overall win measures and overall probability of ties needed by using the specification of marginal win measures and marginal probability of ties that are readily available from clinical investigators or literature. The latter formulas provide a novel way to specify a meaningful and justifiable magnitude of win measures and the magnitude of probability of ties. Therefore, they can be readily used to evaluate the powers based on the number of multiple endpoints, the ordering, and types of endpoints. Our extensive simulation studies show that the power estimations based on these formulas are often like the simulated powers for any type of correlated hierarchical endpoints except for scenarios with very high correlations between endpoints. We illustrate the usefulness of our formulas by using data from three trials with different types of hierarchical endpoints.

SiM Clinical Trials Optimization & Learning Theory · 发表于 2025-05-19

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority

Hakim‐Moulay Dehbi, Sean Devlins, Alexia Iasonos, Matthew Nankivell, Duncan Gilbert, John O'Quigley

摘要

A dose optimization trial in oncology may be performed to compare an approved dose level of a given drug with a reduced dose level, testing the hypothesis that efficacy is maintained whilst reducing side effects and consequently improving adherence and quality‐of‐life. This is particularly relevant with modern therapeutic agents whose mechanisms of action imply that efficacy may not necessarily be linearly related to the dose. Using a conventional non‐inferiority framework leads to large sample sizes that are often unfeasible in the phase IV setting. An alternative is to use a margin of practical non‐inferiority, which we define in this paper and show how it can be exploited to justify a sample size. Whilst defining the extent of the margin, researchers also pre‐specify the other dimensions of interest, such as receptor occupancy and/or side effects and quality‐of‐life, that will be used to establish practical non‐inferiority if the observed efficacy of the reduced dose level lies within the margin. The comparison of efficacy is based on the observed difference between the reduced and the approved levels, instead of the confidence interval of this difference, leading to a reduction in sample size. The reduction in precision due to the smaller sample size is compensated by formally pre‐specifying the additional dimensions to the decision process, allowing a more thorough assessment of the opportunity to reduce a dose in practice, with the many advantages that this may involve.

SiM Other · 发表于 2025-05-19

Multi‐Study Factor Regression Model: An Application in Nutritional Epidemiology

Roberta De Vito, Alejandra Avalos‐Pacheco

摘要

Diet is a risk factor for many diseases. In nutritional epidemiology, studying reproducible dietary patterns is critical to reveal important associations with health. However, this task is challenging: diverse cultural and ethnic backgrounds may critically impact eating patterns by showing heterogeneity, leading to incorrect dietary patterns and obscuring the components shared across different groups or populations. Moreover, covariate effects generated from observed variables, such as demographics and other confounders, can further bias these dietary patterns. Identifying the shared and group‐specific dietary components and covariate effects is essential to drive accurate conclusions. To address these issues, we introduce a new modeling factor regression, the Multistudy Factor Regression (MSFR) model. The MSFR model analyzes different populations simultaneously, achieving three goals: capturing shared component(s) across populations, identifying group‐specific structures, and correcting for covariate effects. We use this novel method to derive common and ethnic‐specific dietary patterns in a multicenter epidemiological study in Hispanic/Latinos community. Our model improves the accuracy of common and group dietary signals, provides a robust estimation of factor cardinality, and yields better prediction than other techniques, revealing important associations with health and cardiovascular disease. In summary, we provide a tool to integrate different groups, providing accurate dietary signals crucial to inform public health policy.

SiM Networks & Graphs · 发表于 2025-05-19

Interconnections of Multimorbidity‐Related Clinical Outcomes: Analysis of Health Administrative Claims Data With a Dynamic Network Approach

Hao Mei, Haonan Xiao, Ben‐Chang Shia, Guanzhong Qiao, Yang Li

摘要

Given the rising complexity and burden of multimorbidity, it is crucial to provide evidence‐based support for managing multimorbidity‐related clinical outcomes. This study introduces a dynamic network approach to investigate conditional and time‐varying interconnections in disease‐specific clinical outcomes. Our method effectively tackles the issue of zero inflation, a frequent challenge in medical data that complicates traditional modeling techniques. The theoretical foundations of the proposed approach are rigorously developed and validated through extensive simulations. Using Taiwan's health administrative claims data from 2000 to 2013, we construct 14 yearly networks that are temporally correlated, featuring 125 nodes that represent different disease conditions. Key network properties, such as connectivity, module, and temporal variation are analyzed. To demonstrate how these networks can inform multimorbidity management, we focus on breast cancer and analyze the relevant network structures. The findings provide valuable clinical insights that enhance the current understanding of multimorbidity. The proposed methods offer promising applications in shaping treatment strategies, optimizing health resource allocation, and informing health policy development in the context of multimorbidity management.

SiM Longitudinal Data Genetics & Omics Latent Variables & Mixtures · 发表于 2025-05-19

Integrative Multi‐Omics and Multivariate Longitudinal Data Analysis for Dynamic Risk Estimation in Alzheimer's Disease

Yuanyuan Guo, Haotian Zou, Mohammad Samsul Alam, Sheng Luo

摘要

Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, characterized by diverse cognitive and functional impairments that manifest heterogeneously across individuals, domains, and time. The accurate assessment of AD's severity and progression requires integrating a variety of data modalities, including multivariate longitudinal neuropsychological tests and multi‐omics datasets such as metabolomics and lipidomics. These data sources provide valuable insights into risk factors associated with dementia onset. However, effectively utilizing omics data in dynamic risk estimation for AD progression is challenging due to issues including high dimensionality, heterogeneity, and complex intercorrelations. To address these challenges, we develop a novel joint‐modeling framework that effectively combines multi‐omics factor analysis (MOFA) for dimension reduction and feature extraction with a multivariate functional mixed model (MFMM) for modeling longitudinal outcomes. This integrative joint modeling approach enables dynamic evaluation of dementia risk by leveraging both omics and longitudinal data. We validate the efficacy of our integrative model through extensive simulation studies and its practical application to the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.

SiM Causal Inference Clinical Trials Survival Analysis · 发表于 2025-05-19

Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time‐to‐Event Outcomes Under ICH E9 (R1)

Yuhao Deng, Shasha Han, Xiao‐Hua Zhou

摘要

In randomized controlled trials (RCTs) that focus on time‐to‐event outcomes, intercurrent events can arise in two ways: as semi‐competing events, which modify the hazard of the primary outcome events, or as competing events, which make the definition of the primary outcome events unclear. Although five strategies have been proposed in the ICH E9 (R1) addendum to address intercurrent events in RCTs, these strategies are not easily applicable to time‐to‐event outcomes when aiming for causal interpretations. In this study, we show how to define, estimate, and make inferences concerning objectives that have causal interpretations within these contexts. Specifically, we derive the mathematical formulations of the causal estimands corresponding to the five strategies and clarify the data structure needed to identify these causal estimands. Furthermore, we introduce nonparametric methods for estimating and making inferences about these causal estimands, including the asymptotic variance of estimators and the construction of hypothesis tests. Finally, we illustrate our methods using data from the LEADER Trial, which aims to investigate the effect of liraglutide on cardiovascular outcomes.

SiM Causal Inference Spatial & Time Series · 发表于 2025-05-19

Continuous‐Time Causal Inference With Marked Point Process Weights: An Example on Sodium‐Glucose Co‐Transporters 2 Inhibitor Medications and Urinary Tract Infection

Sumeet Kalia, Olli Saarela, Tao Chen, Braden O'Neill, Christopher Meaney, Rahim Moineddin, Babak Aliarzadeh, Frank Sullivan, Michelle Greiver

摘要

Treatment‐confounder feedback is present in time‐to‐recurrent or longitudinal event analysis when time‐dependent confounders are themselves influenced by previous treatments. Conventional models produce misleading statistical inference of causal effects due to conditioning on these factors on the causal pathway. Marginal structural models are often applied to quantify the causal treatment effect, estimated using longitudinal weights that mimic the randomization procedure by balancing the covariate distributions across the treatment groups. The weights are usually constructed in discrete time intervals, which is appropriate if the follow‐up visits are scheduled and regular. However, in primary care, visit times can be irregular and informative, and the treatment history consists of duration and doses. This can be modeled through a continuous‐time marked point process. We constructed a continuous‐time marginal structural model to estimate the effect of cumulative exposure to Sodium‐Glucose co‐Transporters 2 Inhibitor (SGLT‐2i) medications on time‐to‐recurrent urinary tract infection (UTI). We used a cohort of type II diabetes patients with chronic kidney disease and constructed a marked point process that characterized the recurrent flare episodes of primary care visits (i.e., point process) with marks for the multinominal dose (none, low, high) of SGLT‐2i medications and recurrent episodes of UTI. We applied the stabilized and optimal treatment weights to estimate the hypothesized causal effect. Our results are concordant with earlier findings in which the recurrent episodes of UTI did not increase when patients were prescribed low dose or high dose of SGLT‐2i medications.

SiM Clinical Trials · 发表于 2025-05-19

Closed MCP‐Mod for Pairwise Comparisons of Several Doses With a Control

Franz Koenig, Sergey Krasnozhon, Bjoern Bornkamp, Frank Bretz, Ekkehard Glimm, Alexandra Graf, Dong Xi

摘要

The MCP‐Mod approach by Bretz et al. is commonly applied for dose–response testing and estimation in clinical trials. The MCP part of MCP‐Mod was originally developed to detect a dose–response signal using a multiple contrast test, but it is not appropriate to make a specific claim that the drug has a positive effect at an individual dose. In this paper, we extend the MCP‐Mod approach to obtain confirmatory p‐values for detecting a dose–response signal as well as for the pairwise comparisons of the individual doses against placebo. We apply the closed test principle from Marcus et al. to the optimal contrast tests based on a candidate set of plausible dose–response shapes available at the planning stage of a clinical trial. We show that the contrast coefficients have to be optimized under suitable constraints to guarantee strong Type 1 error rate control at a pre‐specified significance level. Motivated by a recent clinical trial, we evaluate the operating characteristics of the proposed methods in a comprehensive simulation study.

SiM Causal Inference Missing Data & Measurement Error · 发表于 2025-05-19

Causal Inference With Outcomes Truncated by Death and Missing Not at Random

Wei Li, Yuan Liu, Shanshan Luo, Zhi Geng

摘要

In clinical trials, principal stratification analysis is commonly employed to address the issue of truncation by death, where a subject dies before the outcome can be measured. However, in practice, many survivor outcomes may remain uncollected or be missing not at random, posing a challenge to standard principal stratification analysis. In this article, we explore the identification, estimation, and bounds of the average treatment effect within a subpopulation of individuals who would potentially survive under both treatment and control conditions. We show that the causal parameter of interest can be identified by introducing a proxy variable that affects the outcome only through the principal strata, while requiring that the treatment variable does not directly affect the missingness mechanism. Subsequently, we propose an approach for estimating causal parameters and derive nonparametric bounds in cases where identification assumptions are violated. We illustrate the performance of the proposed method through simulation studies and a real dataset obtained from a human immunodeficiency virus study.

SiM Optimization & Learning Theory Bayesian Methods Clinical Trials · 发表于 2025-05-19

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies

Kai Chen, Kentaro Takeda, Ying Yuan

摘要

Project Optimus, initiated by the US Food and Drug Administration (FDA), seeks to shift the focus of dose finding and selection from the maximum tolerated dose to the optimal dose that offers the most favorable risk‐benefit balance. However, applying this paradigm shift to drug combination trials presents challenges, particularly due to limited sample sizes and a large two‐dimensional dose exploration space. These challenges are amplified when trials involve multiple indications. To address this, we developed a two‐stage Bayesian dose optimization design, called COMIC (Combination Optimization in Multiple IndiCations), to efficiently identify Optimal Biological Dose Combinations (OBDC) for multiple indications. The COMIC design follows a two‐stage strategy: First, optimizing the dose for one indication based on a utility function that measures the risk‐benefit tradeoff, and then using that data to inform and accelerate dose optimization for additional indications. This approach significantly reduces the required sample size. Additionally, we incorporate a pharmacodynamic endpoint (e.g., receptor occupancy) to prioritize which component of the combination should be escalated, further enhancing the efficiency of dose optimization. Simulation studies demonstrate the strong performance and robustness of the COMIC design across various scenarios. We illustrate the method using a CAR‐T therapy trial.

SiM Survival Analysis · 发表于 2025-05-19

Balancing Events, Not Patients, Maximizes Power of the Logrank Test: And Other Insights on Unequal Randomization in Survival Trials

Godwin Yung, Kaspar Rufibach, Marcel Wolbers, Ray Lin, Yi Liu

摘要

We revisit the question of what randomization ratio (RR) maximizes the power of the logrank test (LRT) in event‐driven survival trials under proportional hazards (PH). By comparing three approximations of the LRT (Schoenfeld, Freedman, and Rubinstein) to empirical simulations, we find that the RR that maximizes power is the RR that balances the number of events across treatment arms at the end of the trial. This contradicts the common misconception implied by Schoenfeld's approximation that 1:1 randomization maximizes power. Besides power, we consider other factors that might influence the choice of RR (accrual, trial duration, sample size, etc.). We perform simulations to better understand how unequal randomization might impact these factors in practice. Altogether, we derive 5 insights to guide statisticians in the design of survival trials considering unequal randomization.

SiM Survival Analysis Missing Data & Measurement Error · 发表于 2025-05-19

An Augmented Approach for Regression Analysis of Case‐Cohort Interval‐Censored Failure Time Data

Yichen Lou, Mingyue Du, Peijie Wang, Yuxiang Wu

摘要

The case‐cohort design is a valuable two‐phase sampling scheme often used in situations with low disease incidence and challenges in obtaining covariate data due to cost constraints, and many methods have been proposed for its analysis. However, most of the existing approaches, particularly for interval‐censored data, ignore the presence of non‐expensive covariates that are typically observed for the entire cohort and thus can result in the significant loss of efficiency. To address this, under the framework of the semi‐parametric transformation hazards model, we propose a supersampling approach that augments the case‐cohort samples by introducing an additional sub‐cohort, allowing us to incorporate non‐expensive covariates. In the proposed method, the multiple imputation procedure is employed based on rejection sampling, and the asymptotic properties of the resulting estimator of regression parameters are established. To evaluate the finite sample performance of the proposed method, a simulation study is conducted, and it demonstrates its effectiveness in practical situations. Finally, the proposed methodology is applied to an HIV vaccine trial that motivated this study.

SiM Survival Analysis · 发表于 2025-05-19

Adjustment of Conditional Bias in Hazard Ratios for Group Sequential Testing of Progression‐Free Survival and Overall Survival

Shoki Izumi, Shogo Nomura, Yutaka Matsuyama

摘要

In confirmatory randomized controlled trials of patients with metastatic cancer, progression‐free survival (PFS) and overall survival (OS) are often used as multiple primary endpoints. The overall hierarchical strategy is a typical multiplicity adjustment method that analyzes PFS once and performs an interim OS analysis at the time of PFS analysis using an alpha‐spending function—only if the statistical significance of PFS is demonstrated. A subsequent final OS analysis is conducted if the interim OS analysis does not result in early stopping for efficacy. In this study, we focused on the adjustment of conditional bias (CB) in hazard ratio estimates for OS in both interim and final analyses when a trial applied the overall hierarchical strategy. As CB‐adjusting estimators for a single primary endpoint may have limited performance, we extended the conditional mean‐adjusted estimator to the case of an overall hierarchical strategy. Motivated by an actual oncology trial, we evaluated the performance of the proposed estimators through a simulation study. In the case of early stopping for efficacy, the CB of the proposed estimator was smaller than that of the existing methods with comparable root mean squared error.

SiM Spatial & Time Series Machine Learning · 发表于 2025-05-19

A Co‐Segmentation Algorithm to Predict Emotional Stress From Passively Sensed mHealth Data

Younghoon Kim, Sumanta Basu, Samprit Banerjee

摘要

We develop a data‐driven cosegmentation algorithm of passively sensed and self‐reported active variables collected through smartphones to identify emotionally stressful states in middle‐aged and older patients with mood disorders undergoing therapy, some of whom also have chronic pain. Our method leverages the association between the different types of time series. These data are typically nonstationary, with meaningful associations often occurring only over short time windows. Traditional machine learning (ML) methods, when applied globally on the entire time series, often fail to capture these time‐varying local patterns. Our approach first segments the passive sensing variables by detecting their change points, then examines segment‐specific associations with the active variable to identify cosegmented periods that exhibit distinct relationships between stress and passively sensed measures. We then use these periods to predict future emotional stress states using standard ML methods. By shifting the unit of analysis from individual time points to data‐driven segments of time and allowing for different associations in different segments, our algorithm helps detect patterns that only exist within short‐time windows. We apply our method to detect periods of stress in patient data collected during ALACRITY Phase I study. Our findings indicate that the data‐driven segmentation algorithm identifies stress periods more accurately than traditional ML methods that do not incorporate segmentation.

Biometrics Other · 发表于 2025-05-16

Robust and efficient semi-supervised learning for Ising model

Daiqing Wu, Molei Liu

摘要

In biomedical studies, it is often desirable to characterize the interactive mode of multiple disease outcomes beyond their marginal risk. Ising model is one of the most popular choices serving this purpose. Nevertheless, learning efficiency of Ising models can be impeded by the scarcity of accurate disease labels, which is a prominent problem in contemporary studies driven by electronic health records (EHRs). Semi-supervised learning (SSL) leverages the large unlabeled sample with auxiliary EHR features to assist the learning with labeled data only and is a potential solution to this issue. In this paper, we develop a novel SSL method for efficient inference of Ising model. Our method first models the outcomes against the auxiliary features, then uses it to project the score function of the supervised estimator onto the EHR features, and incorporates the unlabeled sample to augment the supervised estimator for variance reduction without introducing bias. For the key step of conditional modeling, we propose strategies that can effectively leverage the auxiliary EHR information while maintaining moderate model complexity. In addition, we introduce approaches including intrinsic efficient updates and ensemble, to overcome the potential misspecification of the conditional model that may cause efficiency loss. Our method is justified by asymptotic theory and shown to outperform existing SSL methods through simulation studies. We also illustrate its utility in a real example about several key phenotypes related to frequent intensive care unit (ICU) admission on MIMIC-III data set.

SiM Longitudinal Data Diagnostics & Prediction · 发表于 2025-05-16

Risk‐Profile Based Monitoring Intervals for Multivariate Longitudinal Biomarker Measurements and Competing Events With Applications in Stable Heart Failure

Teun B. Petersen, Eric Boersma, Isabella Kardys, Dimitris Rizopoulos

摘要

Patient monitoring is routinely used to detect disease aggravation in many chronic conditions. We propose an adaptive scheduling strategy based on dynamic individual risk predictions that can improve the efficiency of monitoring programs that incorporate multiple longitudinal measurements and competing events. It is motivated by stable chronic heart failure (CHF) patients who are periodically seen to assess the risk of disease aggravation based on multiple patient characteristics and circulating marker protein levels such as NT‐proBNP and troponin. We assess the performance of the adaptive strategy versus fixed schedule alternatives using a simulation study based on the Bio‐SHiFT study, a cohort of stable CHF patients.

SiM Networks & Graphs Missing Data & Measurement Error · 发表于 2025-05-16

Integrating Multimodal EHR Data for Mortality Prediction in ICU Sepsis Patients

Yi Wang, Weihua Li

摘要

Rapid and accurate prediction of mortality risk among intensive care unit (ICU) sepsis patients is crucial for timely intervention and improving patient outcomes. However, due to the multimodal and dynamic time‐series nature of patient visit information and the limited data samples, it is challenging to obtain discriminative patient representations, leading to suboptimal mortality prediction results. To address this issue, we design a time‐aware graph embedding attention model (TGAM) to integrate multimodal data and predict mortality in ICU sepsis patients. Our approach involves modeling and generating patient representations that encompass not only demographic information but also dynamic time‐series data reflecting patient health status. Additionally, the graph convolutional network is used to obtain informative concept embeddings from medical ontologies, and an improved transformer is used to capture the temporal information of the patient's health status and handle missing values, overcoming the limitations of small samples. The experimental results on the MIMIC‐III and MIMIC‐IV datasets demonstrate that TGAM significantly improves prediction accuracy, with AUROC scores of 87.65% and 87.00% on the MIMIC‐III and MIMIC‐IV datasets, respectively, outperforming baseline models by over 5 percentage points. TGAM also achieves higher sensitivity, specificity, and AUPRC metrics, and lower Brier Score compared with baseline models, highlighting its effectiveness in identifying high‐risk patients. These findings suggest that TGAM has the potential to become a valuable tool for identifying high‐risk sepsis patients, enabling clinicians to make more informed and timely intervention decisions.

SiM Bayesian Methods Longitudinal Data · 发表于 2025-05-16

Improved Pharmacovigilance Signal Detection Using Bayesian Generalized Linear Mixed Models

Paloma Hauser, Xianming Tan, Fang Chen, Joseph G. Ibrahim

摘要

Vaccine safety monitoring is a critical component of public health given the extensive vaccination rate among the general population. However, most signal detection approaches overlook the inherently related biological nature of adverse events (AEs). We hypothesize that integrating AE field knowledge into the statistical process can facilitate and improve the accuracy of identifying vaccine‐AE associations. For this purpose, we propose a Bayesian generalized linear multiple low‐rank mixed model (GLMLRM) for analyzing high‐dimensional post‐market drug safety databases. The GLMLRM combines integration of AE ontology in the form of outcome‐level groupings, low‐rank matrices corresponding to these groupings to approximate the high‐dimensional regression coefficient matrix, a factor analysis model to describe the dependence among responses, and a sparse coefficient matrix to capture uncertainty in both the imposed low‐rank structures and user‐specified groupings. An efficient Metropolis/Gamerman‐within‐Gibbs sampling procedure is employed to obtain posterior estimates of the regression coefficients and other model parameters, from which testing of outcome‐covariate pair associations is based. The proposed approach is evaluated through simulation studies and is further illustrated by an application to the Vaccine Adverse Event Reporting System (VAERS).

SiM Bayesian Methods Clinical Trials · 发表于 2025-05-16

Bayesian Estimation of Hierarchical Linear Models From Incomplete Data: Cluster‐Level Interaction Effects and Small Sample Sizes

Dongho Shin, Yongyun Shin, Nao Hagiwara

摘要

We consider Bayesian estimation of a hierarchical linear model (HLM) from partially observed data, assumed to be missing at random, and small sample sizes. A vector of continuous covariates includes cluster‐level partially observed covariates with interaction effects. Due to small sample sizes from 37 patient–physician encounters repeatedly measured at four time points, maximum‐likelihood estimation is suboptimal. Existing Gibbs samplers impute missing values of by a Metropolis algorithm using proposal densities that have constant variances while the target posterior distributions have nonconstant variances. Therefore, these samplers may not ensure compatibility with the HLM and, as a result, may not guarantee unbiased estimation of the HLM. We introduce a compatible Gibbs sampler that imputes parameters and missing values directly from the exact posterior distributions. We apply our Gibbs sampler to the longitudinal patient–physician encounter data and compare our estimators with those from existing methods by simulation.

SiM Clinical Trials · 发表于 2025-05-16

Accounting for Inconsistent Use of Covariate Adjustment in Group Sequential Trials

Marlena S. Bannick, Sonya L. Heltshe, Noah Simon

摘要

Group sequential designs in clinical trials allow for interim efficacy and futility monitoring. Adjustment for baseline covariates can increase power and precision of estimated effects. However, inconsistently applying covariate adjustment throughout the stages of a group sequential trial can result in inflation of type I error, biased point estimates, and anticonservative confidence intervals. We propose methods for performing correct interim monitoring, estimation, and inference in this setting that avoid these issues. We focus on two‐arm trials with simple, balanced randomization and continuous outcomes. We study the performance of our boundary, estimation, and inference adjustments in simulation studies. We end with recommendations about the application of covariate adjustment in group sequential designs.

JRSSB High-Dimensional · 发表于 2025-05-16

A statistical view of column subset selection

Anav Sood, Trevor Hastie

摘要

We consider the problem of selecting a small subset of representative variables from a large dataset. In the computer science literature, this dimensionality reduction problem is typically formalized as column subset selection (CSS). Meanwhile, the typical statistical formalization is to find an information-maximizing set of principal variables. This paper shows that these two approaches are equivalent, and moreover, both can be viewed as maximum-likelihood estimation within a certain semi-parametric model. Within this model, we establish suitable conditions under which the CSS estimate is consistent in high dimensions, specifically in the proportional asymptotic regime where the number of variables over the sample size converges to a constant. Using these connections, we show how to efficiently (1) perform CSS using only summary statistics from the original dataset; (2) perform CSS in the presence of missing and/or censored data; and (3) select the subset size for CSS in a hypothesis testing framework.

SiM Diagnostics & Prediction · 发表于 2025-05-16

A Personalized Predictive Model That Jointly Optimizes Discrimination and Calibration

Tatiana Krikella, Joel A. Dubin

摘要

Precision medicine is accelerating rapidly in the field of health research. This includes fitting predictive models for individual patients based on patient similarity in an attempt to improve model performance. We propose an algorithm which fits a personalized predictive model (PPM) using an optimal size of a similar subpopulation that jointly optimizes model discrimination and calibration, as it is criticized that calibration is not assessed nearly as often as discrimination despite poorly calibrated models being potentially misleading. We define a mixture loss function that considers model discrimination and calibration, and allows for flexibility in emphasizing one performance measure over another. We empirically show that the relationship between the size of subpopulation and calibration is quadratic, which motivates the development of our jointly optimized model. We also investigate the effect of within‐population patient weighting on performance and conclude that the size of subpopulation has a larger effect on the predictive performance of the PPM compared to the choice of weight function.

SMMR Clinical Trials Optimization & Learning Theory · 发表于 2025-05-15

A model-free phase I/II dose optimization design for immunotherapy trials

Yingjie Qiu, Mengyi Lu, Yan Han, Wenxian Zhou, Yi Zhao, Leng Han, Yong Zang

摘要

We present a model-free phase I/II clinical trial design, referred to as the UFO design, to optimize the dose of immunotherapy by jointly modeling toxicity, efficacy, and immune response outcomes. Instead of relying on complex parametric modeling approaches, we propose a model-free approach that uses the inherent correlations among different types of outcomes in immunotherapy and the constrained dose-outcome order to facilitate information sharing across different doses. This approach ensures the efficiency and transparency of the UFO design to be implemented in clinical practice. The UFO design is also extended to accommodate the delayed outcomes. It demonstrates favorable operating characteristics through simulation studies. The R Shniy app for simulation and trial implementation using the UFO design is also provided at iusccc.shinyapps.io/smartdesign .

SMMR High-Dimensional · 发表于 2025-05-14

Reproducible feature selection in heterogeneous multicenter datasets via sign-consistency criteria

Xun Zhao, Yalu Ping

摘要

The identification of risk features associated with disease plays a crucial role in biomedical fields. These features are often used to provide evidence for clinical decision-making. However, in the presence of between-center heterogeneity, covariate effects across data centers may exhibit inconsistent directions, making feature selection challenging. In this work, we propose a novel framework to select reproducible risk features whose underlying effects are consistent across different centers. We quantify the feature reproducibility based on the sign-consistency criterion, which provides an acceptable level of heterogeneity in effect sizes and ensures the reasonable similarity of reproducible signals. Compared with the existing feature selection methods, our proposed method effectively protects data privacy and does not rely on the assumption of data homogeneity. Extensive simulations demonstrated that the proposed method has greater power than existing methods do. We apply the proposed approach to analyze data from the China Health and Retirement Study Longitudinal Study (CHARLS) and identify nine important risk factors that show reproducible associations with depression.

SMMR Causal Inference Clinical Trials Nonparametric & Semiparametric · 发表于 2025-05-14

Rank-based estimators of global treatment effects for cluster randomized trials with multiple endpoints on different scales

Emma Davies Smith, Vipul Jairath, Guangyong Zou

摘要

Cluster randomized trials commonly employ multiple endpoints. When a single summary of treatment effects across endpoints is of primary interest, global methods represent a common analysis strategy. However, specification of the required joint distribution is non-trivial, particularly when the endpoints have different scales. We develop rank-based interval estimators for a global treatment effect referred to here as the “global win probability, or the mean of multiple Wilcoxon Mann–Whitney probabilities, and interpreted as the probability that a treatment individual responds better than a control individual on average. Using endpoint-specific ranks among the combined sample and within each arm, each individual-level observation is converted to a “win fraction” which quantifies the proportion of wins experienced over every observation in the comparison arm. An individual’s multiple observations are then replaced with a single “global win fraction” by averaging win fractions across endpoints. A linear mixed model is applied directly to the global win fractions to obtain point, variance, and interval estimates adjusted for clustering. Simulation demonstrates our approach performs well concerning confidence interval coverage and type I error, and methods are easily implemented using standard software. A case study using public data is provided with corresponding R and SAS code.

SMMR Clinical Trials Testing & Uncertainty · 发表于 2025-05-14

Permutation-based global rank test with adaptive weights for multiple primary endpoints

Satoshi Yoshida, Yusuke Yamaguchi, Kazushi Maruo, Masahiko Gosho

摘要

Multiple efficacy endpoints are investigated in clinical trials, and selecting the appropriate primary endpoints is key to the study's success. The global test is an analysis approach that can handle multiple endpoints without multiplicity adjustment. This test, which aggregates the statistics from multiple primary endpoints into a single statistic using weights for the statistical comparison, has been gaining increasing attention. A key consideration in the global test is determination of the weights. In this study, we propose a novel global rank test in which the weights for each endpoint are estimated based on the current study data to maximize the test statistic, and the permutation test is applied to control the type I error rate. Simulation studies conducted to compare the proposed test with other global tests show that the proposed test can control the type I error rate at the nominal level, regardless of the number of primary endpoints and correlations between endpoints. Additionally, the proposed test offers higher statistical powers when the efficacy is considerably different between endpoints or when endpoints are moderately correlated, such as when the correlation coefficient is greater than or equal to 0.5.

SMMR Survival Analysis High-Dimensional Nonparametric & Semiparametric · 发表于 2025-05-14

Penalized estimation for varying coefficient additive hazards models

Hoi Min Ng, Kin Yau Wong

摘要

Varying coefficient models are commonly used to capture intricate interaction effects among covariates in regression models, allowing for the modification of one covariate’s effect by another. Although these models offer increased flexibility, they also introduce greater estimation and computational complexity as a trade-off. This complexity is particularly evident in genomic studies, where the covariates are often high-dimensional, rendering conventional estimation methods inapplicable. In this paper, we study a penalized estimation method for the varying coefficient additive hazards model. We adopt the group lasso penalty along with the kernel smoothing technique to estimate the varying coefficients. In contrast to existing kernel methods, which only use a “local” neighborhood of subjects to estimate the varying coefficient function at any given point, the proposed method takes a “global” approach that incorporates all subjects and is more efficient. Through extensive simulation studies, we demonstrate that the proposed method produces interpretable results with satisfactory predictive performance. We provide an application to a major cancer genomic study.

Biometrics Survival Analysis Nonparametric & Semiparametric · 发表于 2025-05-14

Improving estimation efficiency for case-cohort studies with a cure fraction

Qingning Zhou, Xu Cao

摘要

In the studies of time-to-event outcomes, it often happens that a fraction of subjects will never experience the event of interest, and these subjects are said to be cured. The studies with a cure fraction often yield a low event rate. To reduce cost and enhance study power, 2-phase sampling designs are often adopted, especially when the covariates of interest are expensive to measure or obtain. In this paper, we consider the generalized case-cohort design for studies with a cure fraction. Under this design, the expensive covariates are measured for a subset of the study cohort, called subcohort, and for all or a subset of the remaining subjects outside the subcohort who have experienced the event during the study, called cases. We propose a 2-step estimation procedure under a class of semiparametric transformation mixture cure models. We first develop a sieve maximum weighted likelihood method based only on the complete data and also devise an Expectation-Maximization (EM) algorithm for implementation. We then update the resulting estimator via a working model between the outcome and cheap covariates or auxiliary variables using the full data. We show that the proposed update estimator is consistent and asymptotically at least as efficient as the complete-data estimator, regardless of whether the working model is correctly specified or not. We also propose a weighted bootstrap procedure for variance estimation. Extensive simulation studies demonstrate the superior performance of the proposed method in finite-sample. An application to the National Wilms’ Tumor Study is provided for illustration.

SMMR Machine Learning Clinical Trials Diagnostics & Prediction · 发表于 2025-05-14

Evaluating the sample size requirements of tree-based ensemble machine learning techniques for clinical risk prediction

Oya Kalaycıoğlu, Menelaos Pavlou, Serhat E Akhanlı, Mark A de Belder, Gareth Ambler, Rumana Z Omar

摘要

Machine learning techniques (MLTs) are increasingly being used to develop clinical risk prediction models for binary health outcomes but the sample size requirements for developing and validating such models remain unclear. This study investigates whether sample size guidelines that target mean absolute prediction error (MAPE) for logistic regression models can be applied to tree-based ensemble MLTs (bagging, random forests, and boosting). Simulations based on two large cardiovascular datasets were used to evaluate the performance of MLTs in terms of MAPE, calibration, the C -statistic and Brier score, across six data-generating mechanisms (DGMs) and varying sample sizes. When the DGM and analysis model matched, boosting required a sample size 2–3 times larger than recommended; random forests and bagging did not achieve the target MAPE even with a 12-fold increase. For a neutral DGM that did not match any of the analysis models, logistic regression with only main effects and boosting resulted in target MAPE values with a 12-fold increase in the recommended sample size. For external validation, our simulations showed that sample size guidelines to achieve a target precision of the estimated C -statistic were suitable, and thus may be used to inform sample size calculations for MLTs.

SMMR Survival Analysis Clinical Trials · 发表于 2025-05-14

Analysis of recurrent events in cluster randomised trials: The PLEASANT trial case study

Kelly Grant, Steven A Julious

摘要

Recurrent events for many clinical conditions, such as asthma, can indicate poor health outcomes. Recurrent events data are often analysed using statistical methods such as Cox regression or negative binomial regression, suffering event or time information loss. This article re-analyses the preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT) trial data as a case study, investigating the utility, extending recurrent events survival analysis methods to cluster randomised trials. A conditional frailty model is used, with the frailty term at the general practitioner practice level, accounting for clustering. A rare events bias adjustment is applied if few participants had recurrent events and truncation of small event risk sets is explored, to improve model accuracy. Global and event-specific estimates are presented, alongside a mean cumulative function plot to aid interpretation. The conditional frailty model global results are similar to PLEASANT results, but with greater precision (include time, recurrent events, within-participant dependence, and rare events adjustment). Event-specific results suggest an increasing risk reduction in medical appointments for the intervention group, in September–December 2013, as medical contacts increase over time. The conditional frailty model is recommended when recurrent events are a study outcome for clinical trials, including cluster randomised trials, to help explain changes in event risk over time, assisting clinical interpretation.

SMMR Bayesian Methods Clinical Trials · 发表于 2025-05-14

A family of Bayesian prognostic and predictive covariate-adjusted response-adaptive randomization designs

Xinyi Pei, Yujie Zhao, Jun Yu, Li Wang, Hongjian Zhu

摘要

The prudent use of covariates to enhance the efficiency and ethics of clinical trials has garnered significant attention, particularly following the FDA’s 2023 guidance on adjusting for covariates. This article introduces a Bayesian covariate-adjusted response-adaptive design aimed at distinguishing between prognostic and predictive covariates during randomization and analysis. The proposed design allocates more patients to the superior treatment based on predictive covariates while maintaining balance across prognostic covariate levels, without sacrificing the power to detect treatment effects. Predictive covariates, which identify patients more likely to benefit from a treatment, and prognostic covariates, which predict overall clinical outcomes, are crucial for personalized medicine and ethical rigor in clinical trials. The Bayesian covariate-adjusted response-adaptive design leverages these covariates to enhance precision and ensure balanced comparison groups, addressing patient heterogeneity and improving treatment efficacy. Our approach builds on the foundation of response-adaptive randomization designs, incorporating Bayesian methodologies to manage the complexities of adaptive designs and control the Type I error rate. Comprehensive numerical studies demonstrate the advantages of our design in achieving ethical, efficient, and balancing goals.

JRSSB Other · 发表于 2025-05-13

Unbiased and consistent nested sampling via sequential Monte Carlo

Robert Salomone, Leah F South, Christopher Drovandi, Dirk P Kroese, Adam M Johansen

摘要

We introduce a new class of sequential Monte Carlo methods which reformulates the essence of the nested sampling (NS) method of Skilling in terms of sequential Monte Carlo techniques. Two new algorithms are proposed: nested sampling via sequential Monte Carlo (NS-SMC) and adaptive nested sampling via sequential Monte Carlo (ANS-SMC). The new framework allows convergence results to be obtained in the setting when Markov chain Monte Carlo (MCMC) is used to produce new samples. An additional benefit is that marginal-likelihood (normalizing constant) estimates given by NS-SMC are unbiased. In contrast to NS, the analysis of our proposed algorithms does not require the (unrealistic) assumption that the simulated samples be independent. We show that a minor adjustment to our ANS-SMC algorithm recovers the original NS algorithm, which provides insights as to why NS seems to produce accurate estimates despite a typical violation of its assumptions. A numerical study is conducted where the performance of the proposed algorithms and temperature-annealed SMC is compared on challenging problems. Code for the experiments is made available online at https://github.com/LeahPrice/SMC-NS.

JASA Functional Data · 发表于 2025-05-13

Prediction of Cognitive Function via Brain Region Volumes with Applications to Alzheimer’s Disease Based on Space-Factor-Guided Functional Principal Component Analysis

Shoudao Wen, Yi Li, Dehan Kong, Huazhen Lin

摘要

Alzheimer’s disease (AD) is a prevalent and irreversible brain disorder and early prediction of cognitive function is vital for detecting the onset. The volumes of brain regions can serve as features for predicting cognitive decline, facilitating early detection and intervention. In order to offer a comprehensive representation of brain tissue changes in AD, we employ volume density curves to investigate the relationship between brain regions and cognitive function. However, analyzing these volume curves is complex due to their highly spatial and intrinsic dependence and piecewise structure. To address these challenges, we propose Space-Factor-Guided Functional Principal Component Analysis (SF-FPCA). This method utilizes factor processes to extract low-dimensional features for intrinsic correlations among regions of interest (ROIs) and applies Functional Principal Component Analysis (FPCA) to these processes to address temporal dependence. Furthermore, by decomposing the loadings into smooth functions of spatial coordinates and a piecewise constant matrix, we identify regions exhibiting smoothness within each region while discontinuities between these regions. We apply SF-FPCA to analyze data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Our results demonstrate that SF-FPCA provides the best fit compared to other methods. In addition, features extracted from volume curves using SF-FPCA enable more accurate prediction of cognitive function compared to scalar volumes alone. Leveraging these extracted features, we identify 36 important ROIs influencing cognitive decline. Our investigation into brain atrophy also reveals distinct mechanisms between the left and right hemispheres, shedding light on the nuanced effects of brain region changes on cognitive decline in AD. *(abstract via OpenAlex)*

SMMR Survival Analysis Nonparametric & Semiparametric · 发表于 2025-05-13

Novel empirical likelihood method for the cumulative hazard ratio under stratified Cox models

Dazhi Zhao, Yichuan Zhao

摘要

Evaluating the treatment effect is a crucial topic in clinical studies. Nowadays, the ratio of cumulative hazards is often applied to accomplish this task, especially when those hazards may be nonproportional. The stratified Cox proportional hazards model, as an important extension of the classical Cox model, has the ability to flexibly handle nonproportional hazards. In this article, we propose a novel empirical likelihood method to construct the confidence interval for cumulative hazard ratio under the stratified Cox model. The large sample properties of the proposed profile empirical likelihood ratio statistic are investigated, and the finite sample properties of the empirical likelihood-based estimators under some different situations are explored in simulation studies. The proposed method was finally applied to perform statistical analysis on a real world dataset on the survival experience of patients with heart failure.

Biometrics Spatial & Time Series Bayesian Methods · 发表于 2025-05-13

Continuous-space occupancy models

Wilson J Wright, Mevin B Hooten

摘要

Occupancy models are used to infer species distributions over large spatial extents while accounting for imperfect detection. Current approaches, however, are unable to model species occurrence over continuous spatial domains while accounting for the discrete spatial domain of the observed data. We develop a new class of spatial occupancy models that embeds a change of spatial support between the observed data and occurrence process. We use a clipped Gaussian process to represent species occurrence in continuous space, which can provide inferences at a finer resolution than the observed occupancy data. Our approach is beneficial because it allows for more realistic models of species occurrence, can account for species occurring in only a portion of a surveyed site, and can relate detection probabilities to these within-site occurrence proportions. We show how our model can be fit using Bayesian methods and develop a computationally efficient MCMC algorithm. In particular, we rely on a Vecchia approximation to implement the spatial Gaussian process describing species occurrence and develop a surrogate data approach for jointly updating the spatial terms and spatial covariance parameters. We demonstrate our model using simulated data and compare our approach to alternative spatial occupancy models. We also use our model to analyze ovenbird occurrence data collected in New Hampshire, USA.

JRSSB Other · 发表于 2025-05-08

SymmPI: predictive inference for data with group symmetries

Edgar Dobriban, Mengxin Yu

摘要

Quantifying the uncertainty of predictions is a core problem in modern statistics. Methods for predictive inference have been developed under a variety of assumptions, often—for instance, in standard conformal prediction—relying on the invariance of the distribution of the data under special groups of transformations such as permutation groups. Moreover, many existing methods for predictive inference aim to predict unobserved outcomes in sequences of feature-outcome observations. Meanwhile, there is interest in predictive inference under more general observation models (e.g. for partially observed features) and for data satisfying more general distributional symmetries (e.g. rotationally invariant observations in physics). Here, we propose SymmPI, a methodology for predictive inference when data distributions have general group symmetries in arbitrary observation models. Our methods leverage the novel notion of distributionally equivariant transformations, which process the data while preserving their distributional invariances. We show that SymmPI has valid coverage under distributional invariance and characterize its performance under distribution shift, recovering recent results as special cases. We apply SymmPI to predict unobserved values associated with vertices in a network, where the distribution is unchanged under relabellings that keep the network structure unchanged. In several simulations in a two-layer hierarchical model, and in an empirical data analysis example, SymmPI performs favourably compared with existing methods.

Biometrics Other · 发表于 2025-05-07

Distance weighted directional regression for Fréchet sufficient dimension reduction

Chao Ying, Zhou Yu, Xin Zhang

摘要

Analysis of non-Euclidean data accumulated from human longevity studies, brain functional network studies, and many other areas has become an important issue in modern statistics. Fréchet sufficient dimension reduction aims to identify dependencies between non-Euclidean object-valued responses and multivariate predictors while simultaneously reducing the dimensionality of the predictors. We introduce the distance weighted directional regression method for both linear and nonlinear Fréchet sufficient dimension reduction. We propose a new formulation of the classical directional regression method in sufficient dimension reduction. The new formulation is based on distance weighting, thus providing a unified approach for sufficient dimension reduction with Euclidean and non-Euclidean responses, and is further extended to nonlinear Fréchet sufficient dimension reduction. We derive the asymptotic normality of the linear Fréchet directional regression estimator and the convergence rate of the nonlinear estimator. Simulation studies are presented to demonstrate the empirical performance of the proposed methods and to support our theoretical findings. The application to human mortality modeling and diabetes prevalence analysis show that our proposal can improve interpretation and out-of-sample prediction.

第 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 页